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Introduction
Actin is one of the most abundant proteins in cells. It is a major 
part of the cytoskeleton and an important component of the   
nucleus. Cytoplasmic actin is involved in a large variety of cellular 
functions that include cell locomotion, maintenance of cell shape, 
cell division, intracellular transport, endocytosis, and exocytosis. 
Nuclear actin is involved in transcription, nuclear export, intra-
nuclear transport, and chromatin remodeling (Hofmann, 2009; 
Louvet and Percipalle, 2009).
To date, almost 100 actin-binding proteins have been iden-
tified (dos Remedios et al., 2003). These proteins regulate the forms 
and functions of actin in the cell, including the nucleocytoplasmic 
translocation of actin. For instance, actin, which does not contain 
a NLS can enter the nucleus complexed to cofilin (Pendleton   
et al., 2003), a protein with a classical bipartite NLS (Matsuzaki 
et al., 1988). Moreover, although actin contains two classical   
leucin-rich nuclear export signals (NESs) that are necessary for the 
export of actin via exportin 1 (Wada et al., 1998), the association 
of actin with profilin appears to be necessary for the export of   
actin via exportin 6 (Stuven et al., 2003).
There is also increasing evidence that posttranslational 
modifications of actin, including glutathionylation (Wang et al., 
2003), nitration (Aslan et al., 2003), nitrosylation (Thom et al., 
2008), and arginylation (Karakozova et al., 2006), play impor-
tant roles in regulating the cellular functions of actin. In addi-
tion, actin is modified by ubiquitin in plants (Dantan-Gonzalez 
et al., 2001), the malaria parasite Plasmodium falsiparum (Field 
et al., 1993), and mammalian skeletal muscle (Kudryashova et al., 
2005). A mono-ubiquitinated form of actin, arthrin, has also 
been described in insect flight muscle (Ball et al., 1987). Inter-
estingly, ubiquitination appears to lead to rearrangement of the 
cytoskeleton rather than degradation of the actin.
Several proteomic studies have identified actin as a poten-
tial candidate for SUMOylation (Panse et al., 2004; Vertegaal   
et al., 2004; Rosas-Acosta et al., 2005). Small ubiquitin-related 
modifier (SUMO) proteins have a molecular mass of 11 kD 
and bind to specific lysine residues of target proteins. This con-
jugation is covalent and reversible. Importantly, the majority of 
SUMOylated proteins are found in the nucleus (Johnson, 2004), 
and SUMOylation has been linked to transcription, cellular 
translocations, and protein–protein interactions that are often 
related to nuclear functions (Hay, 2005).
We investigated if actin is indeed SUMOylated and if   
SUMOylation of actin is connected to its nuclear functions. We 
found that nuclear actin is modified specifically by SUMO2 and 
SUMO3. Using computational modeling and site-directed muta-
genesis, we identified lysines 68 and 284 as the sites that are 
important for SUMOylation. Finally, we demonstrated that   
SUMOylation of actin is important for the retention of actin in 
the nucleus because mutations that prevent SUMOylation lead 
to a rapid export of actin from the nucleus through an exportin 
1–dependent pathway that can be inhibited by leptomycin B.
A
ctin, a major component of the cytoplasm, is also 
abundant in the nucleus. Nuclear actin is involved 
in a variety of nuclear processes including tran-
scription, chromatin remodeling, and intranuclear trans-
port.  Nevertheless,  the  regulation  of  nuclear  actin  by 
posttranslational modifications has not been investigated. 
We now show that nuclear actin is modified by SUMO2 
and SUMO3 and that computational modeling and site-
directed mutagenesis identified K68 and K284 as critical 
sites for SUMOylating actin. We also present a model for 
the actin–SUMO complex and show that SUMOylation is 
required for the nuclear localization of actin.
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molecular mass bands increase in units of 15 kD, which sug-
gests that the SUMO proteins may form polySUMO chains, as 
described previously (Matic et al., 2007).
To establish in vivo SUMOylation, we first analyzed   
HeLa cytoplasmic and nuclear extracts with antibodies to actin. 
Nuclei were purified using two rounds of centrifugation through a   
sucrose cushion, a procedure that removes most cytoplasmic pro-
teins (Pestic-Dragovich et al., 2000). Examination of cytoplasmic 
and nuclear extracts with actin antibodies showed the presence of 
two bands in the HeLa nuclear fractions that are 15 and 30 kD 
larger than native actin (Fig. 1 B, lane 2). Importantly, these slower 
migrating bands correlate in size to actin that is mono- and   
di-SUMOylated in vitro (Fig. 1 B, lane 1). These bands were 
absent from the cytoplasmic fraction (Fig. 1 B, lane 3).
To verify that the slower migrating bands are nuclear spe-
cific, we transfected HeLa cells with two different actin plasmids. 
One plasmid contained -actin with an N-terminal myc-epitope 
Results and discussion
We initially used an in vitro assay to analyze if actin can be   
SUMOylated. Purified nonmuscle -actin (>99% purity) was   
incubated with either SUMO1, -2, or -3, or all three SUMO pro-
teins together in the presence of the SUMO-activating (E1) and 
the SUMO-conjugating (E2) enzymes. Fig. 1 A shows that actin 
is indeed modified by all three SUMO proteins when incubated 
individually. However, when actin was incubated with all three 
SUMO proteins together, there was no signal with the SUMO1 
antibody, which suggests that actin is preferentially modified by 
SUMO2 and/or SUMO3. Control reactions showed that actin is 
not modified in the absence of the E1 and E2 enzymes.
The presence of multiple higher molecular weight bands 
in Fig. 1 A suggested that actin may be mono- and poly- 
SUMOylated. SUMO proteins have a molecular mass of about 
11 kD and are covalently bound to their substrate. The higher 
Figure  1.  -Actin  is  SUMOylated  in  vitro.  
(A) Purified -actin was incubated with SUMO1, 
-2, or -3 individually (lanes 1–3) or with all 
three SUMO proteins (lanes 4–8), and probed 
with  SUMO  antibodies  (lanes  1–6,  bottom) 
and actin antibodies (lanes 7 and 8). SUMO2 
and/or -3 modify actin (lanes 5 and 7), but 
SUMO1 does not (lane 4), when incubated 
together. Actin is not modified in the absence 
of the E1 SUMO-activating and E2-conjugat-
ing enzymes (lanes 6 and 8). (B) Nuclear (NE) 
and cytoplasmic (C) extracts were prepared 
from  HeLa  cells,  and  Western  blots  were 
probed with the 56-4 antibody to actin (lanes 
2 and 3). Actin was recognized by the actin 
antibody in the C and NE. A strong band at 
55 kD and weaker, higher molecular weight 
bands that co-migrate with actin SUMOylated 
in vitro were also recognized in the NE by 
the  actin  antibody.  Immunoblot  analyses  on 
HeLa nuclear (NE) and cytoplasmic (C) frac-
tions  from  cells  expressing  myc-actin  and 
myc-NLS-actin (lanes 4–11) demonstrated the 
presence  of  higher  molecular  weight  bands 
predominantly  in  the  NE.  Equal  amounts  of 
protein were applied to lanes 4–7, and lanes 
8–11 were loaded with equal amounts of myc-
tagged actin. Molecular mass markers are in-
dicated in kD; asterisks, SUMOylated actin in 
A and B. Purified BSA and -actin were used 
as markers in B.195 SUMOYLATION OF ACTIN • Hofmann et al.
(myc-actin), and the other contained -actin with an N-terminal 
myc-epitope and an NLS between the actin and the myc-epitope 
(myc-NLS-actin). The distribution of the myc-actin (Fig. 1 B, 
lanes 6 and 7; and Fig. S1) is similar to endogenous actin, with the 
majority of the actin in the cytoplasm, whereas proportionately 
more of the myc-NLS-actin is targeted to the nucleus (Fig. 1 B, 
lanes 4 and 5, and Fig. S1). Both actin constructs are functional 
because they assemble into the cytoskeleton (Fig. S1 A), as   
described previously (Posern et al., 2002). Moreover, N-terminal 
fusions do not interfere with actin function (Westphal et al., 1997; 
Schoenenberger et al., 1999), and N-terminal fusion proteins, both 
with and without an NLS, have been used successfully to analyze 
the functions of actin in the cytoplasm and the nucleus (Posern   
et al., 2002; Chuang et al., 2006; McDonald et al., 2006; Dundr   
et al., 2007). Importantly, a slower migrating band was detected 
only in the nuclear extract from cells expressing myc-NLS-actin 
(Fig. 1 B, lane 4). Because the absence of a higher molecular 
weight band in lane 6 could be caused by the presence of less actin 
in the nucleus, immunoblots from gels that were loaded with equal 
amounts of myc-tagged actin were probed with myc antibodies. 
These blots demonstrated that the slower migrating bands are still 
only detected in the nuclear fractions from cells expressing   
myc-NLS-actin or myc-actin (Fig. 1 B, lanes 8–11).
To further characterize the in vivo SUMOylation of actin, 
we cotransfected COS-7 cells with myc-actin or myc-NLS-actin 
and His-tagged SUMO1, SUMO2, or SUMO3 constructs. The 
cells were lysed 42 h after transfection, and the His-tagged 
SUMO proteins, which are expressed at equivalent levels under 
similar conditions (Jacobs et al., 2007), were pulled down using 
Ni-agarose beads, resolved by SDS-PAGE, transferred to nitro-
cellulose, and probed with anti-myc antibodies to detect if the 
myc-tagged actin is SUMOylated. Fig. 2 (A and B) shows that 
both the myc-actin and the myc-NLS-actin are modified in cells 
by SUMO2 and SUMO3 but not to a significant level by 
SUMO1. This corroborates the results in Fig. 1 A that demon-
strate that actin is preferably modified by SUMO 2 and 3 in vitro. 
Similarly, Ni pull-down experiments on cells expressing myc-
actin (Fig. 2 A) and myc-NLS-actin (Fig. 2 B) corroborated the 
results in Fig. 1 B by demonstrating that actin that is targeted   
to the nucleus (myc-NLS-actin) is SUMOylated and poly- 
SUMOylated to a greater extent than the myc-actin, probably 
because most of the myc-actin is in the cytoplasm.
Finally, we cotransfected cells with His-tagged SUMO2 
and either myc-actin, myc-NLS-actin, or myc-actin-NES-1 to 
investigate if SUMOylation is indeed connected to the nuclear 
localization of actin. Myc-actin-NES-1 contains point mutations 
Figure 2.  Actin is SUMOylated in vivo. (A and B) COS-7 cells were 
cotransfected  with  His-tagged  SUMO  proteins  and  various  myc-tagged 
actin constructs. His-tagged proteins were purified on a Ni
2+ column and 
analyzed with a myc antibody. Myc-actin (A) and myc-NLS-actin (B) are 
modified in vivo predominantly by SUMO 2 and 3. Modification of actin 
by SUMO2 and SUMO3 is increased when the amount of nuclear actin 
is increased (compare A and B). Vector indicates cells that were only 
transfected with myc-actin or myc-NLS-actin. (C) SUMOylation of nuclear 
targeted  actin:  COS-7  cells  were  cotransfected  with  His-SUMO2  and   
either myc-actin, myc-NLS-actin, or myc-actin-NES-1. Myc-NLS-actin and myc- 
actin-NES-1 are targeted to the nucleus via the NLS or are retained in the 
nucleus because of a mutation in the NES. The two actin constructs that are 
targeted to the nucleus show strong SUMOylation. In contrast, myc-actin, 
which is predominantly cytoplasmic, shows weaker modification. Molecu-
lar mass markers are indicated in kD. Asterisks, SUMOylated actin.
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nuclear localization. In contrast, most of the cells expressing 
EYFP-NLS-actin-K68/284R, which is not SUMOylated (Fig. 3 B), 
did not show nuclear localization. Only 25% of these cells 
showed strong nuclear staining (Fig. 4 A). The exclusion of the 
EYFP-NLS-actin-K68/284R from the nucleus is quite surpris-
ing because it contains a classical nuclear localization signal 
that is normally sufficient to target proteins to the nucleus 
(Kalderon et al., 1984).
The absence of the NLS-actin-K68/284R construct from 
the nucleus could be due to two possibilities: it is either not   
imported into the nucleus or it is imported but then exported   
immediately. Actin contains two functional NESs (Wada et al., 
1998) that are recognized by the export factor CRM1/exportin1 
and are leptomycin B (LMB) sensitive (Kudo et al., 1998). To 
analyze the possibility that the SUMO-deficient actin is rapidly 
exported from the nucleus, time lapse analysis was performed 
on HeLa cells transfected with either EYFP-actin-wt (no NLS) 
or  EYFP-NLS-actin-K68/284R  and  treated  with  LMB  20  h   
after transfection (Fig. 4 B). A z stack of cells expressing EYFP-
actin-wt did not reveal nuclear accumulation after 50 min of LMB 
treatment. This is consistent with the previous demonstration 
that it takes 24 h after LMB to detect actin accumulation in 
the nucleus (Wada et al., 1998). Treatment of cells expressing 
EYFP-NLS-actin-K68/284R with LMB, in contrast, leads to 
the accumulation of the modified actin in the nucleus within 
30–50 min. Thus, SUMO-deficient actin apparently enters the 
nucleus through its attached NLS. Because the accumulation 
only occurs after treatment with LMB, we conclude that the SUMO-
deficient actin is rapidly exported out of the nucleus, thereby 
explaining its absence from the nucleus.
The observation that nuclear actin is modified by SUMO 
could have far reaching ramifications. Mechanistically, the ter-
minal glycine of SUMO is reported to form a covalent bond 
with lysine residues on target proteins (Lin et al., 2002). Consis-
tent with this idea, the model with the lowest free energy score 
predicted that the C-terminal GG motif of SUMO2/3 forms a 
covalent bond with K284 on actin and salt bridges between 
Asp84, Lys20, and Glu80 of SUMO2/3 and Lys68, Asp80, and 
Arg39 on actin. The results presented here support this model 
by demonstrating that SUMO apparently interacts with K284 
and K68 when it modifies actin. Surprisingly, mutating either 
K68 or K284 into arginine appears to prevent SUMOylation. 
One plausible explanation for this observation is that both sites 
are required for the binding of the SUMO enzymes and that 
K68 stabilizes the SUMO–actin interaction so that it can be co-
valently linked to actin at K284. Although we cannot establish 
the binding sequence, our data are consistent with a bimodal 
interaction between actin and SUMO2, and suggest that coopera-
tivity between K284 and K68 is necessary to stabilize the 
SUMO2–actin complex.
Functionally,  the  crystal  structure  of  actin  has  demon-
strated that actin contains four relatively globular subdomains. 
Our  experimental  and  computational  data  demonstrate  that 
SUMO2/3 bridges subdomains 2 and 3 (Fig. 3), which may pro-
vide insights into the nuclear trafficking of actin. Actin that can-
not be SUMOylated enters the nucleus but appears to be rapidly 
exported because it accumulates in the nucleus only after the 
in one of the two NESs of actin (Wada et al., 1998). These muta-
tions  have  been  shown  to  effectively  prevent  nuclear  export, 
thereby leading to nuclear accumulation of the actin (Wada et al., 
1998). Therefore, myc-actin-NES-1 shows an increase in nuclear 
localization similar to myc-NLS-actin. Ni-agarose pull-down 
experiments demonstrated increased SUMOylation of myc-
NLS-actin and myc-actin-NES-1 that are targeted specifically to 
the nucleus (Fig. 2 C). Actin with predominantly cytoplasmic dis-
tribution (myc-actin-wt) shows distinctly weaker SUMOylation. 
Collectively, these data demonstrate that actin is SUMOylated in 
vitro and in vivo by SUMO2 and SUMO3, and that SUMOylation 
apparently correlates with its nuclear localization.
We next sought to identify the sites that are modified by 
SUMO. The core consensus motif for SUMOylation is KxE/D, 
where    is  a  bulky  hydrophobic  residue.  SUMO  covalently 
binds through an isopeptide bond between the C-terminal car-
boxyl group of SUMO and the -amino group of the lysine resi-
due (Lin et al., 2002). We used the SUMOplotAnalysis program 
provided by Abgent (see “Plasmids and transfection”) to iden-
tify two high probability consensus SUMOylation sites in actin 
(L
67K
68Y
69P
70 and M
283K
284C
285D
286). We then applied docking 
paradigms to explore the possible interactions of SUMO2/3 (PDB 
code 2IO1; Reverter and Lima, 2006) with actin (PDB code 
1HLU; Chik et al., 1996). Because the SUMO structure includes 
the part of the sequence that is identical between SUMO2 and 
SUMO3 (the first 14 residues are missing), the model applies for 
both SUMO2/3. To allow some flexibility in the C-terminal re-
gion of SUMO2, the initial rigid-body screening was performed 
without the Q88QTGG92 C-terminal peptide of SUMO2. The 
terminal peptide sequence was then added to the structure in the 
free energy evaluation and ranking steps. Some of the predicted 
models were not able to accommodate the C terminus and were 
therefore eliminated. From the remaining models, the docked 
conformation with the lowest free energy score is shown in Fig. 3 A. 
This model brings the C-terminal peptide of SUMO2/3 within 
reach of K284, one of the two actin residues predicted to be 
conjugated to SUMO.
Importantly, the model suggests that the globular domain 
of SUMO2/3 is stabilized by salt bridges between K68, D80, 
and D39 on actin and D84, K20, and E80 on SUMO2/3, respec-
tively (Fig. 3 A). Such a bimodal interaction suggests that, after 
the covalent binding of SUMO2/3 to K284, a salt bridge be-
tween D84 on SUMO and K68 on actin plays a critical role in 
stabilizing SUMO on the actin surface. To test this model, the 
following single or double point mutations were introduced into 
the myc-NLS-actin construct: K68R, K284R, and K68/284R. 
The arginine-for-lysine substitutions specifically target the lysine 
residues to which SUMO covalently binds. Pull-down experi-
ments using Ni-agarose on COS-7 cells cotransfected with His-
SUMO2 and the respective actin constructs demonstrated that 
substituting lysine for arginine at both K68 and K284 greatly 
decreased SUMOylation (Fig. 3 B).
The in vivo effect of SUMOylating actin was analyzed by 
transfecting HeLa cells with either the EYFP-NLS-actin-wt or 
EYFP-NLS-actin-K68/284R  construct,  and  taking  confocal 
images of live cells 20 h after transfection (Fig. 4 A). Most of the 
cells expressing EYFP-NLS-actin-wt (82%) showed a distinctly 197 SUMOYLATION OF ACTIN • Hofmann et al.
The demonstration that nuclear actin is SUMOylated raises 
the intriguing possibility that it also regulates the nuclear struc-
ture of actin. The absence of classical actin filaments in the   
nucleus, as determined by phalloidin staining, has raised questions 
regarding the form and function of nuclear actin. By spanning 
subdomains two and three of actin, SUMOylation would inter-
fere with the formation of the classical actin filament as predicted 
by the Holmes F-actin model (Lorenz et al., 1993). However, 
SUMOylation might support the formation of unconventional 
actin structures such as antiparallel lower dimer (LD), a structure 
possibly adopted by nuclear actin based on the staining of nuclear 
export receptor for actin, CRM1/exportin1, is blocked by LMB 
(Fig. 4 C). Actin contains two functional leucine-rich NESs, with 
NES-1 and NES-2 spanning residues 170–181 and residues   
211–222, respectively, and disrupting either NES blocks nuclear 
export of actin (Wada et al., 1998). The modeling experiments 
show that SUMO, by spanning subdomains two and three, lies over 
NES-1 (Fig. 3). Thus, SUMOylation could prevent the binding of 
nuclear export factors to NES-1 so that SUMO–actin is retained 
in the nucleus. Moreover, preventing SUMOylation would make 
this export signal readily accessible so that actin is rapidly ex-
ported from the nucleus.
Figure 3.  Model of the -actin–SUMO2/3 complex. (A) Predicted model of -actin (blue) in complex with SUMO2/3 (red). Amino acids involved in 
complex formation are specified. (B) SUMOylation of actin mutants: myc-tagged wild-type -actin with an NLS (lane 1) or K68R, K284R, or a K68/284R 
double mutant -actin (lanes 2–4), each with a myc tag and NLS, were coexpressed in COS-7 cells with His-SUMO2. His-SUMO2 was purified on a Ni
2+ 
column and probed with anti-myc antibodies. COS-7 cells were cotransfected with His-SUMO2 and myc-NLS-actin constructs containing the indicated 
amino acid substitutions. Molecular mass markers are listed in kD. Asterisk, SUMOylated actin. (C) Schematic representation of the location of the SUMO 
protein relative to the location of NES-1 of -actin. Note that the SUMOylation appears to cover NES-1.JCB • VOLUME 186 • NUMBER 2 • 2009   198
contaminations, isolated nuclei were subjected twice to sedimentation 
through a 1.9-M sucrose cushion before preparing the nuclear extract (Pestic- 
Dragovich et al., 2000).
Antibodies
The 56-4 antibody that reacts with -actin (Hofmann et al., 2004) was 
used to detect SUMOylated actin. The anti-c-myc antibody was obtained 
from Santa Cruz Biotechnology, Inc., SUMO1 and SUMO2/3 antibodies 
were obtained from BIOMOL International L.P., and peroxidase-conjugated 
secondary anti–mouse or anti–rabbit antibodies were obtained from Jackson 
ImmunoResearch Laboratories.
Plasmids and transfection
The actin fusion proteins were derivatives of pEFYP-actin (Clontech Laborato-
ries, Inc.) with the addition of the NLS sequence (5-CCAAAAAAGﾭAAGﾭ-
AAAGﾭGﾭTA-3) between the EYFP and the actin. Myc-tagged actin constructs 
were generated by cloning actin or NLS-actin into the pSGﾭ5 vector (Agilent 
Technologies).  Plasmids  expressing  His-tagged  SUMO-1,  SUMO-2,  and 
SUMO-3 were generated in pcDNA3 and were a gift from R. Hay (Univer-
sity of Dundee, Scotland, UK). Point mutations in actin were generated using 
the QuickChange site-directed mutagenesis kit (Agilent Technologies). COS-7 
cells were seeded in 10-cm plates and transfected 24 h later using   
FuGﾭENE 6 (Roche) with plasmids encoding the various actin and SUMO 
actin, but not cytoplasmic actin, by a LD-specific antibody that 
stains actin (Schoenenberger et al., 2005; Jockusch et al., 2006). 
Although  this  is  a  fascinating  possibility,  further  studies  are 
needed to establish the role of SUMOylation in the formation of 
nucleus-specific actin structures.
In conclusion, we have demonstrated that nuclear actin is 
SUMOylated. We have also shown that SUMOylation regulates 
the nuclear trafficking of actin. Modeling and experimental data 
have also provided important insights into how SUMOylation 
affects the physiological properties of actin in the nucleus.
Materials and methods
Cell culture and cell extracts
HeLa  and  COS-7  cells  were  cultured  in  Dulbecco’s  modified  Eagle’s   
medium supplemented with10% fetal bovine serum and 1% penicillin/
streptomycin, at 37°C with 5% CO2. HeLa nuclear and cytoplasmic ex-
tracts were prepared as described previously (Dignam et al., 1983), 
with a minor modification. To obtain nuclei that are free of cytoplasmic 
Figure 4.  Localization of EYFP-actin in live cells. (A) Distribution of EYFP-NLS-actin-wt and EYFP-NLS-actin-K68/284R. Confocal images of live cells taken 
20 h after transfection (left). The distribution of the two proteins was quantified in 100 transfected cells per experiment (error bars indicate mean ± SEM,   
n = 3). (B) Time course of cellular localization of EYFP-actin-wt and EYFP-NLS-actin-K68/284R after leptomycin B treatment (2 ng/ml).199 SUMOYLATION OF ACTIN • Hofmann et al.
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proteins (5 µg of DNA, each). Western blot analyses of cell extracts showed 
that equivalent amounts of actin proteins and SUMO proteins were ex-
pressed (Jacobs et al., 2007) within groups.
In vitro SUMOylation assay
In vitro SUMOylation assays were performed using a kit from BIOMOL   
International L.P. -Actin (99% pure) was obtained from Cytoskeleton, Inc.
Ni pull-down assays
COS-7 cells were extracted under denaturing conditions 42 h after they 
were transfected, and His-tagged (SUMOylated) proteins were isolated   
using nickel (Ni-NTA) agarose beads (QIAGﾭEN) as described previously   
(Rodriguez et al., 1999). The isolated proteins were separated by SDS–PAGﾭE, 
and myc-tagged/SUMOylated actin was detected by immunoblotting using 
standard conditions.
Docking method and predicted model
The  scheme  used  to  predict  docked  conformations  between  -actin   
(PDB code 1HLU) and SUMO2 (PDB code 2CKH) was developed in the 
Camacho Laboratory. An earlier automated implementation of the method, 
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using  the  fast-Fourier  transform–based  program  DOT  (Mandell  et  al., 
2001); a free energy evaluation of docked structures using the FastContact 
(Camacho and Zhang, 2005) scoring function; clustering (Comeau et al., 
2004; Kozakov et al., 2005) the low free energy complex structures; and 
ranking based on cluster size and free energy score.
Live cell imaging
HeLa cells were plated on Delta T Dishes (0.17 mm, black; Bioptechs) and 
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lens (Carl Zeiss, Inc.). For time-lapse analysis of LMB treatment, cells were 
treated 20 h after transfection with 2 ng/ml leptomycin B (BIOMOL Inter-
national, L.P.). Confocal images were taken every 15 min, and after 50 min, 
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